You are here » Home » Companies » Company Overview » Aurobindo Pharma Ltd

Aurobindo Pharma Ltd.

BSE: 524804 Sector: Health care
NSE: AUROPHARMA ISIN Code: INE406A01037
BSE 00:00 | 18 Jun 614.35 0.90
(0.15%)
OPEN

615.00

HIGH

618.40

LOW

603.75

NSE 00:00 | 18 Jun 613.85 0
(0.00%)
OPEN

614.00

HIGH

618.55

LOW

603.20

OPEN 615.00
PREVIOUS CLOSE 613.45
VOLUME 121918
52-Week high 808.95
52-Week low 527.05
P/E 19.86
Mkt Cap.(Rs cr) 35,995
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 615.00
CLOSE 613.45
VOLUME 121918
52-Week high 808.95
52-Week low 527.05
P/E 19.86
Mkt Cap.(Rs cr) 35,995
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Aurobindo Pharma Ltd. (AUROPHARMA) - Company History

Aurobindo Pharma Limited (APL) one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy Mr. K.Nityananda Reddy and a small highly committed group of professionals founded it. APL is developing manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives) intermediates and generic formulations. The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics Anti-Retro Virals CVS CNS Gastroenterologicals and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO) Geneva has also approved Aurobindo's products. APL is running with 14 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped R&D facility. Aurobindo Pharma has identified international operations also catering to over 100 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively the Company has filed a total of 337 DMFs (Drug Master Files) of which 110 are with US FDA and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry and it became a public venture in 1992. In the same year 1992 another unit was also set up for the manufacture of CMIC Chloride a bulk drug intermediate at Pashamylaram near Hyderabad through another company namely Chaitanya Organics Pvt. Ltd. Later in 1994-95 it was merged with the company. The commercial production of the pharmaceutical formulation unit was started in April of the year 1994. Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. Glaxo (India) the Indian subsidiary of the UK-based multinational came to an alliance with the company to meet its global bulk drug requirements during the year 1997. In the year 1998 the company had launched new formulations like auronim Suspension in the paediatric segment. During 1999-2000 the company diversified its product portfolio further with the introduction of wide range of Cephalosporins (Oral & Sterile) and anti - virals in addition to macrolides anti-ulcerants quinolones semi-synthetic penicillins and formulations for domestic and export market. APL made Joint Ventures for formulations business in US with an investment of a million in the year 2000. Sri Chakra Remedies Ltd was amalgamated with the company in the identical year of 2000. The Company has launched an exclusive anti-viral division Immune during the year 2001 to educate and to provide preventive drug care for HIV/AIDS patients in the country. APL had launched two more drugs in the same year of 2001 namely Efavirenz (Viranz) and Nelfinavir (NELVEX) for the treatment of AIDS. During the year 2001-02 the company acquired 79% stake in Ranit Pharma Company under the same management. Ranit Pharma and Calc Private Ltd were amalgamated with APL as at 1st April of the year 2002.Citadel Aurobindo Biotech Ltd a 50:50 Joint Venture (JV) Company introduced Aztreonam a Monabactam Betalactam antibiotic for the first time in the Indian Pharma Market with a brand name 'TREONAM' in the year 2003. During the same year the JV was happened between APL and Shanxi Tongling Pharmaceuticals Company as an upshot formulated the JV Company under the name of Aurobindo Tongling (Datong) pharmaceuticals Ltd China for manufacture of pharmaceutical products to the local market. APL's 100% subsidiary company in China had commenced its commercial production during the year 2003-2004 which was formulated to procure raw material 6 APA at an economical cost. APL also launched the second JV Company in US for the purpose of Research and Development. During the year 2004 the company received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology. During the year 2004-05 the company acquired a sterile plant of Dee Pharma for the consideration of Rs.38 million which located at Bhiwadi in Rajasthan. US FDA part of Department of health and human science approved the Unit VIII facility of the company in the year of 2005 as a site to manufacture of APIs for the US Market. Also in the same year APL had received US FDA clearance for AIDS drug. The State Labour Department of the Government of Andhra Pradesh has awarded the 'Best Management Award' for the year 2005 for the Company's contributions towards community development harmonious employee relations and their welfare. During the year 2005-06 the company made a strategic entry with its generic formulations in the premium markets of USA & Europe participated in the PEPFAR program initiated by the Government of USA and consolidated its strengths in the less regulated and emerging markets. Also in same year APL had acquired the UK based Milpharm Limited the generic formulation pharmaceutical company engaged in marketing generic formulations mainly in the UK market. During March of the year 2007 the US FDA has granted final approval for the Company's Didanosine Oral Suspension (Pediatric Powder) 10 mg / ml. As at June 13th of the year 2007 the Company unveiled their new Logo and Corporate Identity at a ceremony in Hyderabad. The new corporate logo reflects this pace and leadership. Artistic lines intersect to make up the company's initials 'A' and 'P'. The way the initials 'A' and 'P' have joined conveys the spirit of 'partnership' with the company's business. The Hon'ble High Court of Andhra Pradesh has approved the scheme of arrangement for merger of APL Life Sciences and Senor Organics into the company and the utilisation of share premium account of the company during June of the year 2007. APL concluded a strategic deal for acquisition of intellectual property & marketing suthorizations with TAD Italy a generic company registered in Italy during March of the year 2008. This acquisition will give Aurobindo an access to more than 70 ready to market products which will fast track Aurobindo's entry into the Italian generic market. As a part of this deal APL also acquired high profile OTC brands - Mapooro and Carmiooro from TAD in same period of the year 2008. On 6 September 2010 Aurobindo Pharma announced that it has entered into licensing and supply agreements with AstraZeneca one of the world's leading biopharmaceutical companies to supply several solid dosage and sterile products for emerging markets.On 11 January 2011 Aurobindo Pharma announced that it had entered into a definitive agreement with China National Pharmaceutical Group Corporation (Sinopharm) to divest in its subsidiary company Aurobindo (Datong) Bio Pharma Co Ltd China (ADBPL) subject to regulatory approvals. ADBPL is engaged in manufacturing of 6APA a derivative of Penicillin-G. Aurobindo Pharma decided to retain 19.50% stake in ADBPL so as to ensure uninterrupted supply of raw materials at competitive price. On 7 September 2011 Aurobindo Pharma announced the establishment of an equal joint venture in Russia with OJSC DIOD to manufacture and sell pharmaceuticals in Russia Belarus and Kazakhstan.On 1 April 2014 Aurobindo Pharma announced the completion of the acquisition of certain commercial operations in Western Europe from Actavis plc a global integrated specialty pharmaceutical company focused on developing manufacturing and distributing generic brand and biosimilar products. The agreement to acquire the Actavis operations was announced in January 2014.On 5 December 2014 Aurobindo Pharma announced the completion of acquisition of assets of nutritional supplement maker Natrol Inc. and other affiliate entities (Natrol) through its wholly owned subsidiary Aurobindo Pharma USA Inc. (APUSA). On 12 November 2014 APUSA emerged as the highest and best bidder to acquire assets of Natrol under the auction process by the United States Bankruptcy Court for the District of Delaware. APUSA acquired the manufacturing assets personnel commercial infrastructure including the well established nutraceuticals brands in USA of Natrol along with an agreement to take on certain liabilities with a bid of $132.5 million.On 25 November 2016 Arrow Generiques SAS a French subsidiary of Aurobindo Pharma Ltd announced the signing of an agreement to acquire the right title and interest in its products Calcium and Calcium Vitamin D3 in France including the use of the OROCAL trademark from Teva Pharmaceutical Industries.On 7 January 2017 Aurobindo Pharma announced the signing of a binding agreement by and through its wholly owned step-down subsidiary Agile Pharma B.V Netherlands to acquire Generis Farmaceutica SA a Portuguese pharmaceutical company for a total consideration 135 million Euro including net working capital of 21.7 million Euro.On 9 February 2017 Aurobindo Pharma announced the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop commercialize and market these products globally.